Research Article
State of the Art on the Evidence Base in Cardiac Regenerative Therapy: Overview of 41 Systematic Reviews
Table 1
Key features of the 41 included reviews.
| | Feature | Median or count (%) | Minimum | 1st quartile | 3rd quartile | Maximum |
| | Year of publication | 2011 | 2006 | 2009 | 2013 | 2014 | | Authors | 6 | 2 | 4 | 8 | 26 | | North American/European corresponding author | 21 | — | — | — | — | | Studies included | 10 | 2 | 7 | 18 | 50 | | Patients included | 660 | 179 | 412 | 985 | 2,625 | | Randomized trials only | 36 | — | — | — | — | | Type of setting | | | | | | | Acute myocardial infarction | 22 (54%) | — | — | — | — | | Chronic ischemic heart disease or heart failure | 19 (46%) | — | — | — | — | | Type of therapy | | | | | | | Any stem cell | 6 (15%) | — | — | — | — | | Bone marrow-derived stem cell | 29 (71%) | — | — | — | — | | Granulocyte-colony stimulating factor | 5 (12%) | — | — | — | — | | Other | 1 (2%) | — | — | — | — | | Patient-level meta-analysis | 2 (5%) | — | — | — | — | | Random effects | 36 (88%) | | | | | | Small study effect testing | 34 (83%) | | | | | | Subgroup analysis | 38 (93%) | — | — | — | — | | Metaregression | 8 (20%) | — | — | — | — | | Conflict of interests | 2 (5%) | — | — | — | — | | Funding | 27 (66%) | — | — | — | — | | A Measurement Tool to Assess Systematic Reviews (AMSTAR) score | 9 | 3 | 9 | 10 | 11 | | Favorable findings on prognosis | 12 (29%) | — | — | — | — | | Favorable findings on symptoms | 2 (5%) | — | — | — | — | | Favorable findings on cardiac function parameters or signs | 32 (78%) | — | — | — | — | | Change in left ventricular ejection fraction | 3.47% | 0.02% | 2.90% | 4.22% | 6.11% | | Yearly Web of Science citations | 4.1 | 0 | 2.2 | 6.5 | 68.9 | | Yearly Scopus citations | 5.1 | 0 | 2.5 | 7.4 | 81.8 | | Yearly Google Scholar citations | 7.3 | 0 | 3.2 | 11.3 | 105.2 |
|
|
